QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rafael-holdings-q3-eps-019-up-from-136-yoy-sales-36200k-up-from-33600k-yoy

Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 86.03 percent increase over losses of $(1....

 rafael-holdings-updates-terms-of-rights-offering-granting-1-non-transferable-subscription-right-per-share-or-equivalent-public-warrant-held-as-of-may-9-2025-allowing-holders-to-purchase-0603-shares-of-class-b-common-stock-at-128-per-share-with-public-warrant-holders-receiving-03525-rights-per-warrant-and-full-rights-granted-per-3-warrants-held

Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today provided an update to the subscription rights related to its Public Warrants i...

 rafael-holdings-revises-subscription-rights-following-prior-25m-rights-offering-to-support-development-and-potential-launch-of-trappsol-cyclo

Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announ...

 rafael-holdings-announces-proposed-terms-of-25m-rights-offering-to-support-its-commitment-to-development-and-potential-launch-of-trappsol-cyclo

Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offeri...

 rafael-holdings-q4-eps-019-down-from-006-yoy-sales-16500k-up-from-6800k-yoy

Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 416.67 percent decrease over earnings of $...

Core News & Articles

On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange r...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION